THE ULTIMATE GUIDE TO TRACLEER

six The phosphodiesterase-5 inhibitor sildenafil is licensed for PAH in FC I–IV during the USA and FC II–III in Europe. Endothelin receptor antagonists (ERAs) together with bosentan, sitaxentan and ambrisentan are oral therapies certified for use in PAH. As no oral agent has proven superiority there remains debate as to which need to be utilize